keyword
MENU ▼
Read by QxMD icon Read
search

Lurasidone

keyword
https://www.readbyqxmd.com/read/29146409/safety-and-effectiveness-of-long-term-treatment-with-lurasidone-in-older-adults-with-bipolar-depression-post-hoc-analysis-of-a-6-month-open-label-study
#1
Brent P Forester, Martha Sajatovic, Joyce Tsai, Andrei Pikalov, Josephine Cucchiaro, Antony Loebel
OBJECTIVE: To evaluate the safety and effectiveness of 6 months of treatment with lurasidone in older adults with a diagnosis of bipolar I depression. DESIGN: Post-hoc analysis of a multicenter, 6-month, open-label extension study. SETTING: Outpatient. PARTICIPANTS: Patients aged 55 to 75 years with a DSM-IV-TR diagnosis of bipolar I depression who had completed 6 weeks of double-blind, placebo-controlled treatment with either lurasidone monotherapy (1 study) or adjunctive therapy with lithium or valproate (2 studies)...
October 10, 2017: American Journal of Geriatric Psychiatry
https://www.readbyqxmd.com/read/29098883/solid-dispersion-adsorbate-technique-for-improved-dissolution-and-flow-properties-of-lurasidone-hydrochloride-characterization-using-3-2-factorial-design
#2
Ashok Mahajan, Naazneen Surti, Pooja Koladiya
The aim of the present investigation was to improve the dissolution and flow properties of Lurasidone hydrochloride by solid dispersion adsorbate technique. Solid dispersions of Lurasidone hydrochloride were prepared by fusion method using Poloxamer P188. The melt dispersion was adsorbed onto the porous carrier Florite (calcium silicate). A 3(2) factorial design was employed to quantify the effect of two independent variables, namely ratio of carrier (Poloxamer 188) and Lurasidone hydrochloride in solid dispersion and ratio of adsorbent (Florite) to solid dispersion...
November 3, 2017: Drug Development and Industrial Pharmacy
https://www.readbyqxmd.com/read/29077621/a-systematic-review-of-atypical-antipsychotics-in-chronic-pain-management-olanzapine-demonstrates-potential-in-central-sensitization-fibromyalgia-and-headache-migraine
#3
Xavier F Jimenez, Tharani Sundararajan, Edward C Covington
INTRODUCTION: Many psychopharmacologic agents are used as primary or adjunct agents in pain management. Atypical antipsychotics (AAs) have also been used as adjuncts in pain management regimens in a variety of manners; however, their efficacy in this capacity is unclear. METHODS: A systematic review of all studies examining AA use for pain was conducted. Three literature databases were utilized to search for word combinations of "pain" and a variety of commonly-prescribed AAs (olanzapine, quetiapine, risperidone, aripiprazole, ziprasidone, clozapine, paliperidone, iloperidone, lurasidone)...
October 26, 2017: Clinical Journal of Pain
https://www.readbyqxmd.com/read/29075309/weight-changes-before-and-after-lurasidone-treatment-a-real-world-analysis-using-electronic-health-records
#4
Jonathan M Meyer, Daisy S Ng-Mak, Chien-Chia Chuang, Krithika Rajagopalan, Antony Loebel
BACKGROUND: Severe and persistent mental illnesses, such as schizophrenia and bipolar disorder, are associated with increased risk of obesity compared to the general population. While the association of lurasidone and lower risk of weight gain has been established in short and longer-term clinical trial settings, information about lurasidone's association with weight gain in usual clinical care is limited. This analysis of usual clinical care evaluated weight changes associated with lurasidone treatment in patients with schizophrenia or bipolar disorder...
2017: Annals of General Psychiatry
https://www.readbyqxmd.com/read/29073755/neutropenia-with-multiple-antipsychotics-including-dose-dependent-neutropenia-with-lurasidone
#5
Shabnam Sood
Antipsychotic-induced agranulocytosis is a significant side effect that is known to occur with most of the antipsychotic medications. It usually resolves once the medications are stopped and patients are able to be switched over to another antipsychotic medication. Lurasidone has not been reported to cause leukopenia and neutropenia. This case report is of a patient with a past history of risperidone induced-aganulocytosis developing dose related leukopenia and neutropenia with lurasidone.
November 30, 2017: Clinical Psychopharmacology and Neuroscience: the Official Scientific Journal of the Korean College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/29069112/systematic-review-of-recent-guidelines-for-pharmacological-treatments-of-bipolar-disorders-in-adults
#6
Stephen Hammett, Nagy A Youssef
BACKGROUND: To examine the similarities and differences among practice guidelines for managing bipolar disorders (BDs) in adults. METHODS: A literature search in PubMed/Medline was performed using multiple search terms and bibliographies for guidelines from July 2013 (since FDA approval of lurasidone) to June 2017. RESULTS: Six treatment guidelines for BDs in adults were identified. These guidelines showed consensus on first-line treatment of mania (moodstabilizer and/or an antipsychotic), and most first-line medications for bipolar depression...
November 2017: Annals of Clinical Psychiatry: Official Journal of the American Academy of Clinical Psychiatrists
https://www.readbyqxmd.com/read/28992737/asenapine-iloperidone-and-lurasidone-exposures-in-young-children-reported-to-u-s-poison-centers
#7
Gina Stassinos, Wendy Klein-Schwartz
CONTEXT: Asenapine, iloperidone and lurasidone are relatively new atypical antipsychotics. There is limited information on toxicity on pediatric exposures to these drugs. The objective of this study was to compare toxicity associated with asenapine, iloperidone and lurasidone exposures in young children. METHODS: A retrospective study of U.S. National Poison Data System from 2010 to 2015 of single substance exposures to asenapine, iloperidone or lurasidone in children <6 years of age that were followed to known outcome was performed...
October 10, 2017: Clinical Toxicology
https://www.readbyqxmd.com/read/28985992/lurasidone-a-new-option-for-older-adults-with-bipolar-disorder
#8
EDITORIAL
Soham Rej
No abstract text is available yet for this article.
September 11, 2017: American Journal of Geriatric Psychiatry
https://www.readbyqxmd.com/read/28981857/transformed-panss-factors-intended-to-reduce-pseudospecificity-among-symptom-domains-and-enhance-understanding-of-symptom-change-in-antipsychotic-treated-patients-with-schizophrenia
#9
Seth C Hopkins, Ajay Ogirala, Antony Loebel, Kenneth S Koblan
Positive and Negative Syndrome Scale (PANSS) total score is the standard primary efficacy measure in acute treatment studies of schizophrenia. However, PANSS factors that have been derived from factor analytic approaches over the past several decades have uncertain clinical and regulatory status as they are, to varying degrees, intercorrelated. As a consequence of cross-factor correlations, the apparent improvement in key clinical domains (eg, negative symptoms, disorganized thinking/behavior) may largely be attributable to improvement in a related clinical domain, such as positive symptoms, a problem often referred to as pseudospecificity...
September 11, 2017: Schizophrenia Bulletin
https://www.readbyqxmd.com/read/28946779/muscarinic-receptor-signaling-contributes-to-atypical-antipsychotic-drug-reversal-of-the-phencyclidine-induced-deficit-in-novel-object-recognition-in-rats
#10
Masanori Miyauchi, Nichole M Neugebauer, Tatsuya Sato, Hossein Ardehali, Herbert Y Meltzer
Enhancement of cholinergic function via muscarinic acetylcholine receptor M1 agonism improves cognition in some schizophrenia patients. Most atypical antipsychotic drugs, including clozapine and its active metabolite, N-desmethylclozapine, and lurasidone, enhance the release of acetylcholine in key brain regions involved in cognition (e.g. hippocampus). We determined the effect of muscarinic acetylcholine receptor M1 stimulation on novel object recognition and its contribution to the ability of atypical antipsychotic drugs to reverse the novel object recognition deficit in rats withdrawn from subchronic phencyclidine, a rodent model of cognitive impairment in schizophrenia...
September 1, 2017: Journal of Psychopharmacology
https://www.readbyqxmd.com/read/28935656/the-effect-of-chronic-treatment-with-lurasidone-on-rat-liver-cytochrome-p450-expression-and-activity-in-the-chronic-mild-stress-cms-model-of-depression
#11
Marta Kot, Anna Haduch, Mariusz Papp, Władysława Anna Daniel
Recent studies indicated an important role of the monoaminergic nervous systems (dopaminergic, noradrenergic and serotonergic systems) and stress in the regulation of cytochrome P450 (CYP) expression and activity in the liver. The aim of our present research was to determine the effect of the novel atypical neuroleptic drug with antidepressant properties lurasidone, on the expression (mRNA and protein level) and activity of liver CYP isoforms involved in the metabolism of drugs and endogenous steroids, in the chronic mild stress (CMS) model of depression...
September 21, 2017: Drug Metabolism and Disposition: the Biological Fate of Chemicals
https://www.readbyqxmd.com/read/28927482/treating-depressive-episodes-or-symptoms-in-patients-with-schizophrenia
#12
Geeske van Rooijen, Jentien Marloes Vermeulen, Henricus Gerardus Ruhé, Lieuwe de Haan
Depressive episodes or symptoms occur frequently in patients with schizophrenia and may have far-reaching consequences. Despite the high prevalence rate and clinical relevance of this comorbidity, knowledge about treatment options is still limited. The aim of this review is to provide an overview of the literature concerning treatment options for depressive episodes or symptoms in schizophrenia. Based on the current evidence, we present a stepwise treatment approach. The first step is to evaluate the current antipsychotic treatment of psychotic symptoms and consider lowering the dosage, since increased blockade of the dopamine D2 receptors may be associated with a worse subjective sense of well-being and dysphoria...
September 20, 2017: CNS Spectrums
https://www.readbyqxmd.com/read/28902525/lurasidone-efficacy-and-safety-in-the-treatment-of-psychotic-and-mood-disorders
#13
Maurizio Pompili, Claudio Verzura, Giada Trovini, Andrea Buscajoni, Giulia Falcone, Stefano Naim, Adele Nardella, Serena Sorice, Ross J Baldessarini, Paolo Girardi
Lurasidone ([3aR,4S,7R,7aS]-2-[(1R,2R)-2-[4-(1,2-benzisothiazol-3-yl)piperazin-1yl-methyl] cyclohexylmethyl]-hexahydro-4,7-methano-2H-isoindole-1,3-dione hydrochloride; Latuda® [LRSD]) is a novel benzisothiazole, second-generation antipsychotic drug developed by Dainippon Sumitomo Pharma Corporation in Japan. Similar to other atypical antipsychotics it has a distinctive pharmacodynamic profile, Areas covered: This review updates reported research findings on the efficacy, safety and tolerability of LRSD for treatment of psychotic and major affective disorders, with meta-analyses...
September 13, 2017: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/28807142/efficacy-of-lurasidone-in-the-treatment-of-agitation-a-post-hoc-analysis-of-five-short-term-studies-in-acutely-ill-patients-with-schizophrenia
#14
Michael H Allen, Leslie Citrome, Andrei Pikalov, Jay Hsu, Antony Loebel
OBJECTIVE: This post hoc analysis evaluated the effect of lurasidone on agitation in acutely ill patients with schizophrenia. METHOD: Patient-level data were pooled from five 6-week, randomized, double-blind, placebo-controlled studies of fixed-dose, once-daily, oral lurasidone (40, 80, 120, or 160 mg/d). Agitation was assessed with the Positive and Negative Syndrome Scale-Excited Component (PANSS-EC) score, utilizing a mixed model for repeated measurement analysis...
July 2017: General Hospital Psychiatry
https://www.readbyqxmd.com/read/28806387/lurasidone-associated-neuroleptic-malignant-syndrome
#15
Mei Lee, Dorian Marshall, Sahoo Saddichha
No abstract text is available yet for this article.
October 2017: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28796415/white-matter-tract-integrity-is-associated-with-antidepressant-response-to-lurasidone-in-bipolar-depression
#16
Martin J Lan, Harry Rubin-Falcone, Fatima Motiwala, Ying Chen, Jonathan W Stewart, David J Hellerstein, J John Mann, Patrick J McGrath
OBJECTIVES: Patients with bipolar disorder spend the most time in the depressed phase, and that phase is associated with the most morbidity and mortality. Treatment of bipolar depression lacks a test to determine who will respond to treatment. White matter disruptions have been found in bipolar disorder. Previous reports suggest that white matter disruptions may be associated with resistance to antidepressant medication, but this has never been investigated in a prospective study using a Food and Drug Administration (FDA)-approved medication...
September 2017: Bipolar Disorders
https://www.readbyqxmd.com/read/28740811/change-in-daytime-sleepiness-and-cognitive-function-in-a-6-month-double-blind-study-of-lurasidone-and-quetiapine-xr-in-patients-with-schizophrenia
#17
Philip D Harvey, Cynthia O Siu, Antony D Loebel
Daytime sleepiness is a commonly reported adverse effect associated with psychotropic agents that may impair cognitive performance and functioning. The objective of this post-hoc analysis was to evaluate the long-term effects of lurasidone and quetiapine XR on daytime sleepiness and neurocognitive performance during a 6-month, double-blind continuation study, in subjects who completed an initial 6-week, randomized, placebo-controlled trial comparing these agents. Daytime sleepiness, cognitive performance, and health-related quality of life were assessed with the Epworth Sleepiness Scale (ESS), CogState computerized battery, and the Quality of Well-Being (QWB-SA) Scale, respectively...
September 2016: Schizophrenia Research. Cognition
https://www.readbyqxmd.com/read/28738099/a-case-series-on-the-effectiveness-of-lurasidone-in-patients-with-stuttering
#18
Janet Charoensook, Gerald A Maguire
BACKGROUND: The prevalence of stuttering is approximately 1% of the population, affecting an estimated 3 million individuals in the United States. The dopamine hypothesis of stuttering explains that abnormally increased cerebral dopamine affects the balanced levels that maintain the basal ganglia circuits, which helps with timing cues in initiating speech. This is especially significant when considering treatment strategies. We report a reduction in stuttering with lurasidone, a potent D2 receptor antagonist with a relatively favorable adverse effects profile...
August 2017: Annals of Clinical Psychiatry: Official Journal of the American Academy of Clinical Psychiatrists
https://www.readbyqxmd.com/read/28727644/cariprazine-specificity-profile-in-the-treatment-of-acute-schizophrenia-a-meta-analysis-and-meta-regression-of-randomized-controlled-trials
#19
Filippo Corponi, Alessandro Serretti, Stuart Montgomery, Chiara Fabbri
Cariprazine is a new dopamine D2 and D3 receptor partial agonist antipsychotic. Meta-analytic evidence of efficacy in acute schizophrenia and specific groups of patients is lacking. We carried out a meta-analysis in patients with acute schizophrenia to evaluate the efficacy of cariprazine over placebo and active comparators in overall symptoms, positive and negative symptoms and quality of life. Low and high (≥6 mg/day) doses were tested separately. The possible effect of clinical-demographic modulators was also tested...
November 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28721057/safety-tolerability-and-risks-associated-with-first-and-second-generation-antipsychotics-a-state-of-the-art-clinical-review
#20
REVIEW
Marco Solmi, Andrea Murru, Isabella Pacchiarotti, Juan Undurraga, Nicola Veronese, Michele Fornaro, Brendon Stubbs, Francesco Monaco, Eduard Vieta, Mary V Seeman, Christoph U Correll, André F Carvalho
Since the discovery of chlorpromazine (CPZ) in 1952, first-generation antipsychotics (FGAs) have revolutionized psychiatric care in terms of facilitating discharge from hospital and enabling large numbers of patients with severe mental illness (SMI) to be treated in the community. Second-generation antipsychotics (SGAs) ushered in a progressive shift from the paternalistic management of SMI symptoms to a patient-centered approach, which emphasized targets important to patients - psychosocial functioning, quality of life, and recovery...
2017: Therapeutics and Clinical Risk Management
keyword
keyword
27111
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"